Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial

Robert Haddad; Anne O'Neill; Guilherme Rabinowits; Roy Tishler; Fadlo Khuri; Douglas Adkins; Joseph Clark; Nicholas Sarlis; Jochen Lorch; Jonathan J Beitler; Sewanti Limaye; Sarah Riley; Marshall Posner

doi:10.1016/S1470-2045(13)70011-1

Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial

Robert Haddad, Anne O'Neill, Guilherme Rabinowits, Roy Tishler, Fadlo Khuri, Douglas Adkins, Joseph Clark, Nicholas Sarlis, Jochen Lorch, Jonathan J Beitler, Sewanti Limaye, Sarah Riley, Marshall Posner

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Lancet Oncology
Volume	14
DOIs	https://doi.org/10.1016/S1470-2045(13)70011-1
State	Published - Jan 3 2013
Externally published	Yes

Disciplines

Medicine and Health Sciences
Pathology

Access to Document

10.1016/S1470-2045(13)70011-1License: Unspecified

Cite this

Haddad, R., O'Neill, A., Rabinowits, G., Tishler, R., Khuri, F., Adkins, D., Clark, J., Sarlis, N., Lorch, J., Beitler, J. J., Limaye, S., Riley, S., & Posner, M. (2013). Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncology, 14. https://doi.org/10.1016/S1470-2045(13)70011-1

Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. / Haddad, Robert; O'Neill, Anne; Rabinowits, Guilherme et al.
In: Lancet Oncology, Vol. 14, 03.01.2013.

Research output: Contribution to journal › Article › peer-review

Haddad, R, O'Neill, A, Rabinowits, G, Tishler, R, Khuri, F, Adkins, D, Clark, J, Sarlis, N, Lorch, J, Beitler, JJ, Limaye, S, Riley, S & Posner, M 2013, 'Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial', Lancet Oncology, vol. 14. https://doi.org/10.1016/S1470-2045(13)70011-1

@article{7740f889d59541fdb5c7ed0426ae118d,

title = "Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial",

author = "Robert Haddad and Anne O'Neill and Guilherme Rabinowits and Roy Tishler and Fadlo Khuri and Douglas Adkins and Joseph Clark and Nicholas Sarlis and Jochen Lorch and Beitler, \{Jonathan J\} and Sewanti Limaye and Sarah Riley and Marshall Posner",

note = "Background: The relative efficacy of the addition of induction chemotherapy to chemoradiotherapy compared with chemoradiotherapy alone for patients with head and neck cancer is unclear. The PARADIGM study is a multicentre open-label phase 3 study comparing the use of docetaxel, cisplatin, and fluorouracil (TPF) induction chemotherapy followed by concurrent chemoradiotherapy with cisplatin-based concurrent chemoradiotherapy alone in patients with locally advanced head and neck cancer.",

year = "2013",

month = jan,

day = "3",

doi = "10.1016/S1470-2045(13)70011-1",

language = "American English",

volume = "14",

journal = "Lancet Oncology",

}

TY - JOUR

T1 - Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial

AU - Haddad, Robert

AU - O'Neill, Anne

AU - Rabinowits, Guilherme

AU - Tishler, Roy

AU - Khuri, Fadlo

AU - Adkins, Douglas

AU - Clark, Joseph

AU - Sarlis, Nicholas

AU - Lorch, Jochen

AU - Beitler, Jonathan J

AU - Limaye, Sewanti

AU - Riley, Sarah

AU - Posner, Marshall

N1 - Background: The relative efficacy of the addition of induction chemotherapy to chemoradiotherapy compared with chemoradiotherapy alone for patients with head and neck cancer is unclear. The PARADIGM study is a multicentre open-label phase 3 study comparing the use of docetaxel, cisplatin, and fluorouracil (TPF) induction chemotherapy followed by concurrent chemoradiotherapy with cisplatin-based concurrent chemoradiotherapy alone in patients with locally advanced head and neck cancer.

PY - 2013/1/3

Y1 - 2013/1/3

UR - https://pubmed.ncbi.nlm.nih.gov/23414589/

U2 - 10.1016/S1470-2045(13)70011-1

DO - 10.1016/S1470-2045(13)70011-1

M3 - Article

VL - 14

JO - Lancet Oncology

JF - Lancet Oncology

ER -

Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial

Disciplines

Access to Document

Other files and links

Cite this